NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Unconfirmed

**Date:** Tuesday 14 November 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Iftab Akram Present for all items
4. Dr Alex Cale Present for items 1.1 to 4.2.2
5. Dawn Cooper Present for all items
6. Dr Mark Corbett Present for all items
7. Dr Prithwiraj Das Present for items 1.1 to 4.2.2 and

 5.1.2 to 5.2.2

1. Chamkhor Dhillon Present for all items
2. Dr David Foreman Present for all items
3. Dr Rob Forsyth Present for all items
4. Dr Pedro Saramago Goncalves Present for all items
5. John Hampson Present for all items
6. Dr Nigel Langford Present for items 4.1.2 to 5.2.2
7. Iain McGowan Present for all items
8. Ugochi Nwulu Present for all items
9. Stella O’Brien Present for all items
10. Dr Clare Offer Present for all items
11. Amit Parekh Present for all items
12. Dr Kate Ren Present for all items
13. Professor Andrew Renehan Present for all items
14. Dr Arpit Srivastava Present for all items
15. Elizabeth Thurgar Present for all items

NICE staff (key players) present

Ross Dent, Associate Director Items 1.1 to 5.2.2

Louise Jafferally, Project Manager Items 1.1 to 5.2.2

Alexandra Filby, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Kirsty Pitt, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Emily Crowe, Associate Director Items 5.1 to 5.2.2

Leena Issa, Project Manager Items 5.1 to 5.2.2

Sally Doss, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Emma Douch, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Dan Gallacher, Warwick Evidence Items 1.1 to 4.1.4

Henry Nwankwo, Warwick Evidence Items 1.1 to 4.1.4

Archie Walters, BMJ-TAG Items 5.1 to 5.1.4

Victoria Wakefield, BMJ-TAG Items 5.1 to 5.1.4

Clinical, Patient & NHS England experts present

Peter Clark, NHSE Clinical Lead for cancer drugs Items 1.1 to 4.2.2

Karen Hasid, HEART UK Ambassador – patient expert, nominated by HEART UK Items 5.1 to 5.1.4

Adam Barratt, HEART UK Ambassador – patient expert, nominated by HEART UK Items 5.1 to 5.1.4

Jaimini Cegla, Consultant in Metabolic Medicine – clinical expert, nominated by HEART UK Items 5.1 to 5.1.4

Hendrean Soran, Consultant Physician and Endocrinologist – clinical expert, nominated by HEART UK and Ultragenyx Items 5.1 to 5.1.4

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Steve O’Brien welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Britta Stordal, Michael Chambers, Satish Venkateshan, Dr Steve Lloyd.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 10 October 2023.

### Appraisal of Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments [ID3943]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Swedish Orphan Biovitrum (Sobi).
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10831/documents).
		3. The chair led a discussion of the consultation comments presented to the committee.
		4. The committee discussed confidential information submitted for this item.
	2. Part 2a - Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments [ID3943] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta10831)

### Appraisal of Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Ultragenyx.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10655/documents).
		3. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Ugochi Nwulu, Clare Offer and Elizabeth Thurgar.
		4. The committee discussed confidential information submitted for this item.
	2. Part 2a - Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta10655)

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 12 December 2023 and will start promptly at 9:00am.